glp 1 vs glp 1/gip GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal Frontiers | Mechanisms of action

These small gestures create trust that lasts far longer than any single win

Supports cell-to-cell communication within the brain (thats whats meant by interhemispheric transfer of information)

In vitro cytotoxicity assays using SH-SY5Y (human neuroblastoma), Caco-2 (intestinal permeability), and hCMEC/D3 (human brain endothelial) cells demonstrated that nanoencapsulation significantly reduced the inherent cytotoxicity of free coumarin

The convergence of GLP-1 signaling with pathways of aginginsulin sensitivity, mitochondrial function, neuroinflammationsuggests these drugs may influence healthspan, not just body weight. (de Cabo & Mattson, 2019) For women entering their 50s and 60s, this convergence is especially powerful

Rosenstock, J., Reusch, J., Bush, M., Yang, F., Stewart, M

By synergistically integrating GLP-1, amylin, and calcitonin receptor signaling, it effectively overcomes the efficacy ceilings of current monotherapies, offering profound weight reduction and glycemic control comparable to surgical interventions. For now, we must wait and see